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Transforming Growth Factor p Inhibits Megakaryocyte Growth and Endomitosis
By David J. Kuter, Dianne M. Gminski, and Robert D. Rosenberg Using a rat bone marrow culture system, the effect of transforming growth factor p1 (TGFp1) on megakaryocyte growth and endoreduplication has been studied. Purified human platelet TGFpl inhibited the number of megakaryocytes that appeared in culture at a half-maximal concentration of 0.66 ? 0.21 ng/mL and inhibited megakaryocyte endoreduplication at a half-maximal concentration of 0.14 f 0.08 ng/mL. Under identical conditions, growth of erythroid precursors was half-maximally inhibited at a concentration of 0.125 ng/mL while myeloid growth was not inhibited at concentrations of TGFpl up t o 25 ng/mL. These profound inhibitory effects on megakaryocyte growth and endomitosis suggested that TGFp might play a role in megakaryocytopoiesis. Therefore, we explored the effect of TGFp in three different experimental situations by using a neutralizing antibody t o TGFp: (1) Serum but not plasma was found t o inhibit the number and ploidy of megakaryocytes that grew in vitro. This inhibitory activity was completely neutralized HE MEGAKARYOCYTE is the precursor cell of the T circulating platelet and is unique among bone marrow cells in possessing a polyploid nucleus. In response to an increased demand for platelets, the mean ploidy of megakaryocytes first increases' and is then followed by a rise in the number of megakaryocytes.' In contrast, the number of megakaryocytes and their mean ploidy decrease with a decreasing demand for platelets. The bone marrow megakaryocyte and the circulating platelet mass are linked by a feedback loop that is mediated by humoral mediator(s) whose activity can be measured by the extent of megakaryocyte polyploidization. ' The humoral mediator for platelet production has been assumed to be a stimulator of megakaryocyte growth? Such substances have been identified in human embryonic kidney conditioned medium7-" as well as in thrombocytopenic plasma.'z~'s While adequate amounts of none of these substances have been purified to allow further characterization, several well-defined growth factors have recently been shown to stimulate megakaryocyte growth. Recombinant human erythropoietin increases the number, size, and ploidy of megakaryocytes16-18 in vitro and pharmacologic doses in vivo may elevate the platelet count.1y~20 Interleukin-6 (IL-6) in vitro increases megakaryocyte size"." and ploidy,22 and in the presence of IL-la or IL-3 potentiates the number of CFU-Mk.ZZ,Z3 In vivo, pharmacologic doses of IL-6 may increase the platelet count and megakaryocyte ~i z e . '~.~ While most research has been directed toward finding substances that stimulate megakaryocyte growth and platelet production, far less attention has been paid to molecules that inhibit the growth of megakaryocytes. Indeed, the enhanced megakaryocyte growth seen with some of the partially purified substances noted previously may simply reflect the absence of inhibitory substances rather than the presence of stimulatory molecules. Several well-defined molecules have been shown to inhibit megakaryocyte growth. Platelet factor-4 (PF-4) and synthetic peptides of PF-426 as well as transforming growth factor P l (TGFp1)27"1 have been found to inhibit the growth of CFU-Mk. Recombinant by antibody t o TGFp or on treatment with dithiothreitol. (2) Plasma from thrombocytotic rats was observed t o decrease megakaryocyte ploidy on culture but this effect was not prevented by the addition of antibody t o TGFp. (3) Plasma from thrombocytopenic but not normal rats increased megakaryocyte ploidy on culture. Addition of antibody t o TGFp did not alter these results. Therefore, TGFp is a potent inhibitor of the number and ploidy of megakaryocytes and accounts for all the inhibition seen when megakaryocytes are cultured in serum. However, the differences in effect on megakaryocyte growth that we observe between normal, thrombocytopenic, and thrombocytotic plasmas are not due t o variations in the amount of TGFp. Furthermore, our results show that release of TGFp from megakaryocytes during culture does not act as an autocrine regulator of megakaryocyte ploidy in vitro. a-interferon inhibits megakaryocyte growth in vitro 32-34 and reduces platelet counts in patients with essential thrombocytosi~.~'
We have recently devisedI8 a rat bone marrow culture system in which megakaryocyte endomitosis may be studied by using flow cytometry. We have reported that plasma from thrombocytopenic rats increased the ploidy of megakaryocytes that grew while plasma from thrombocytotic rats decreased the ploidy of megakaryocyte^.^ During the course of these experiments we found that serum and platelet lysates but not plasma were potent inhibitors of the number and ploidy of the megakaryocytes which grew.18 Because TGFPl is present in large amounts in platelet~,36.~' we sought to determine whether TGFPl might account for the differences between serum and plasma or between the plasmas obtained from normal, thrombocytotic, or thrombocytopenic rats.
acidic fibroblast growth factor (FGF) were obtained from R & D Systems (Minneapolis, MN). We have previously d e m~n s t r a t e d~~ that the antibody to porcine TGFp also neutralizes TGFpl purified from rat platelets. Murine epidermal growth factor (EGF, receptor grade) was from Collaborative Research, Inc (Bedford, MA). Sprague-Dawley-derived (CD) tats were obtained from Charles River Breeding Laboratories, Inc (Wilmington, MA) and were housed in single cages with free access to food and water for at least 1 week before use. New Zealand White rabbits (3 kg) were from Hazleton Research Products, Inc (Denver, PA).
Under ether anesthesia, male rats were bled by cardiac puncture into citrate (final concentration, 0.38%). The citrated whole blood (WB) was centrifuged at 7OOg for 8 minutes at 4°C to prepare platelet-rich plasma (PRP). PRP or citrated WB were twice centrifuged at 3,000g for 15 minutes at 4°C to prepare platelet-poor plasma (PPP). Serum (S), PRP-derived serum (PRPDS), and PPP-derived serum (PPPDS) were obtained from WB, PRP, and PPP, respectively, by recalcification in glass tubes and incubation at 37°C for 2 hours. Clots were removed and the specimens heated at 56°C for % hour. All samples were stored at -80°C and retained full growth-promoting or growth-inhibiting activity for over 2 years. Unless otherwise specified in the text, the terms "serum" and "plasma" refer to PRP-derived serum (PRPDS) and PPP-derived serum (PPPDS), respectively. Each experiment performed with PRPDS has also been done with S and identical results obtained.
As previously described: ether-anesthetized rats (250 to 300 g) were rendered acutely thrombocytopenic by injection of antiplatelet serum (APS). The amount of APS injected was titered to produce platelet counts less than 1% of normal which persisted for 24 hours, at which time the animals were bled by cardiac puncture. Rats were made thrombocytotic by the injection of rat platelets' to produce a platelet count greater than 300% of normal that persisted for 24 hours, at which time the animals were bled by cardiac puncture. For platelet counting, blood samples were obtained from the rat tail vein into the Unopette Collection System (Becton-Dickinson, Rutherford, NJ). Platelets were counted (two chambers per sample) by hemacytometer' using a phase contrast microscope and the increase or decrease in count was expressed as a percentage of the normal, pretreatment count for each animal. Rats used in these experiments had a normal platelet count of 1.5 f 0.16 x 10"iL (average of 89 rats).
Megakaryocyte-depleted rat bone marrow was prepared by the Percoll density-gradient centrifugation and filtration method." The megakaryocyte-depleted bone marrow cells were resuspended to a density of 7 X 106/mL (containing no more than 100 identifiable megakaryocytes/mL) in 3 mLof Iscove's Modified Dulbecco's Medium (IMDM; GIBCO, Grand Island, NY) containing penicillin (200 UlmL), streptomycin (200 p,g/mL), additional glutamine (0.592 mg/mL), and (unless otherwise indicated) 15% (vol/vol) rat PPPDS. Cultures were routinely grown for 3 days at 37°C in a 5% CO, incubator. Subsequently, cells were harvested and stained for flow cytometry with APS and propidium iodide as described previously.'"
To stimulate megakaryocyte endomitosis, cultures were sometimes supplemented with GM-CSF and/or erythropoietin. Addition of GM-CSF (20 U/mL) and erythropoietin (2 U/mL) produced maximal megakaryocyte endomitosis'" as well as maximal myeloid and erythroid growth and are referred to as "GFstimulated" cultures. Addition of erythropoietin alone ("eposupplemented" cultures) at 0.33 U/mL resulted in half-maximal stimulation of megakaryocyte endomitosis.
The hemoglobin content of bone marrow cultures was deterPreparation ofplasma and serum.
Production of thrombocytopenic and thrombocytotic rats.
Bone marrow culture. Each experiment was performed from a single bone marrow preparation and allowed us to assay up to 20 individual specimens under identical culture conditions. Between identical plasma specimens assayed in the same preparation, there is routinely a coefficient of variation (CV) of less than 1%. Between identical plasma specimens assayed in different bone marrow preparations there is routinely a CV of 5% to 8%. (These differences reflect variations in the duration of culture and in the number of megakaryocyte precursors in the marrow [see reference 18.1)
Each lot of antibody to TGFp was titered against purified TGFpl to determine the optimal neutralizing concentration. Twenty to 160 pL of antibody was added to 0.45-mL aliquots of rat PPPDS containing 4 ng of TGFpl, incubated at 18°C for 1 hour and then added to GF-stimulated cultures. The extent of neutralization of the TGFpl-mediated megakaryocyte inhibition was determined.
To determine whether rat serum or plasma samples contained TGFP, 0.45-mL aliquots were incubated at 18°C for 1 hour with antibody to TGFp. The amount of antibody added was twice that calculated to be required if all the activity of the sample was due to inhibition by TGFP. Specimens were then added to cultures with or without erythropoietin. Similarly, thrombocytopenic and thrombocytotic rat plasmas were incubated with antibody to TGFp and added to cultures without erythropoietin.
Rat serum was exposed to 0.066 mol/L DTT for 1 hour at 18°C and subsequently dialyzed (3,000 molecular weight cutoff membranes) for 36 hours with three changes of a 500-fold excess of Hanks' Balanced Salt Solution (without calcium or magnesium). Control rat plasma and serum were prepared in parallel experiments but without DTT exposure.
Flow cytometry was performed as previously described'.lx on a machine designed by H. S h a p i d and built by Y.G. Caine. A coefficient of variation of the 2N peak was maintained at 2.2% to 3.0% by careful alignment of the optical system. Cells were routinely run at 800 to 1,200 cells/s and 1,000 megakaryocytes were analyzed.
Data from the flow cytometer were stored and analyzed on an Atari 130 XE computer (Sunnyvale, CA). Boundaries between each ploidy class were assigned from the DNA histogram and the number of megakaryocytes in each ploidy group was counted. Initially, a limitation in the computer program permitted counting of only 8N and higher megakaryocytes. During the course of these experiments, the program was altered to permit enumeration of the number of 4N megakaryocytes as well. The number of megakaryocytes in each ploidy class was then expressed as a percentage of the total number of megakaryocytes 2 4 N or 2 8N. The geometric mean ploidy for each distribution 4N to 32N (Mean Ploidy,,,) or 8N to 32N (Mean Ploidy,,,) was determined as described by Arriaga et Except for ploidy distributions, statistical analysis of differences was performed with Student's t -t e~t .~" Differences between ploidy distributions were tested for using the Mann-Whitney U test4' as previously described.'
Antibody to TGFp

Treatment of sera with dithiothreitol (DTT).
Flow cytometry.
Data analysis.
RESULTS
Analysis of megakaryocyte growth in liquid bone marrow cultures. After growth in liquid bone marrow culture, the total number of cells, the total number of megakaryocytes, and the ploidy distribution of the megakaryocytes were quantitated by flow cytometry ( Cultures were grown as described in Materials and Methods in 15% (vol/vol) plasma and, where indicated, erythropoietin (2 U/mL), GM-CSF (20 U/mL), and/or TGFpl (5 ng/mL). Data are shown 5 SD. n = The number of independent specimens analyzed for each condition in this experiment. The entire experiment has been performed over 10 times with the same results.
Statistical significance: 'P < ,001 compared with plasma alone; tP < .05 compared with plasma alone; SP < .01 compared with plasma alone; 5P < .02 compared with plasma + EPO/GM; IIP < .05 compared with plasma + EPO/GM. measured by flow cytometry as the total number of cells. As indicated in Table 1 , this number rose on addition of GM-CSF to the cultures. Megakaryocytes comprised the minority cell population in the culture but were precisely quantitated. After flow cytometry, the total number of megakaryocytes per culture and the ploidy distribution (expressed as the percentage of the total number of megakaryocytes in each ploidy class as well as the mean ploidy) were determined. Furthermore, on addition of erythropoietin (see Table 1 and Fig 2) , the erythroid precursors proliferated and the cultures were visibly reddened. By measuring the amount of hemoglobin produced, a fourth parameter reflecting erythroid growth could be quantitated. (Because erythroid cells are a minor population in the culture, their proliferation did not cause an increase in the total number of cells.)
Purified TGFpI inhibits the number and ploidy of megakuryocyfes. When cultured in the presence of plasma (Table 1) megakaryocytes grew and the megakaryocyte ploidy distribution showed an 8N class containing 51.44% of the megakaryocytes. Addition of TGFPl resulted in a statistically significant (P < .001) decrease in the number of megakaryocytes to 63% of the plasma control and a small but statistically significant (P < .OS) shift in the ploidy distribution toward lower ploidy classes. There was no effect on the total cell number. To assess further this suggested inhibitory effect of TGFP1, cultures were stimulated with growth factors. The addition of GM-CSF to the cultures increased the total cell number, whereas the addition of erythropoietin produced a large shift in the ploidy distribution toward higher ploidy classes (Table 1) . When TGFPl was added to these GF-stimulated cultures there was no change in the total number of cells but the number of megakaryocytes decreased (P < .02) and the megakaryocyte ploidy distribution dropped from a Mean Ploidy,,, of 14.05 to 11.58 (P < .OS).
Using these GF-stimulated cultures, the concentration dependence of this effect of TGFpl was explored (Fig 1) . There was no effect on the total number of cells (data not shown) but the number of megakaryocytes decreased ( Fig  1A) with a half-maximal inhibitory concentration of 0.66 2 0.21 ng/mL (average of four experiments) and a maximal decrease in the number of megakaryocytes to 55.8% 2 9.2% (average of six experiments) of normal. Further use only.
For personal at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From addition of TGFPl to concentrations up to 25 ng/mL produced no more inhibition. The effect on individual ploidy classes is shown in Fig 1B. As the concentration of TGFPl increased, the 8N compartment increased while the 16N and 32N compartments decreased in size. The Mean Ploidy,., decreased from 12.12 ? 0.01 to 10.35 with a half-maximal inhibitory effect at 0.14 f 0.08 ng/mL (average of four experiments). Addition of TGFPl up to 25 ng/mL failed to cause further inhibition.
These inhibitory effects of TGFPl were not potentiated by the addition of murine EGF. Concentrations of EGF ranging from 0.1 to 100 ng/mL in the presence of maximal (0.75 ng/mL) or submaximal (0.06 ng/mL) concentrations of TGFPl had no effect on the total cell number, the number of megakaryocytes, or the megakaryocyte ploidy distribution (data not shown).
Purified TGFpl inhibits erythroid but not myeloid growth. The effect of TGFPl on other lineages in the liquid culture system were also determined. While the GM-CSF-dependent increase in total cells (Table 1) was not inhibited by TGFPl up to 25 ng/mL, the erythropoietin-dependent hemoglobinization of the cultures was inhibited by TGFpl at a half-maximal concentration of 0.125 ng/mL (Fig 2) . TGFPl produced a maximal decrease in hemoglobin production to 54% of control. These effects of TGFPl were not potentiated by the addition of murine EGF.
Serum but not plasma inhibits the number and ploidy of megakaryocytes in culture.
When cultured at a concentration of 15% (vol/vol), rat serum produced 81% as many megakaryocytes (P < .001) with a lower Mean Ploidy,.,, (P < .05) than did rat plasma (Table 2) . When cultured at a concentration of 30% (vol/vol), the ploidy values were the same as at the lower protein concentration and still showed a statistically significant difference (P < .05). The relative difference in the number of megakaryocytes (P < .05) also persisted despite a protein concentration-dependent decrease in the total number of megakaryocytes seen in both plasma and serum. To demonstrate that the lesser growth in serum was due to the presence of an inhibitor, equivalent amounts of plasma and serum were mixed (final concentration = 30%). The ploidy distribution of megakaryocytes cultured in this 1:l MIX was the same as in the serum. Taking into account the effect of the increase in the protein concentration, the total number of megakaryocytes in the 1:l MIX was less than that in the plasma (30%) and equal to the serum (30%).
TGFpl accounts for all the inhibitory activity found in serum. Antibody to porcine TGFP has previously been shown to neutralize TGFPl in serum extracts'' and in conditioned medium?' To confirm that this antibody would also neutralize TGFPl in the presence of undiluted plasma, antibody was added to plasma samples containing a known amount of purified human platelet TGFP1. As shown in Fig  3, complete neutralization of 4 ng of TGFpl was attained using 30 pg of antibody. Addition of equivalent amounts of rabbit antibody to human PDGF and bovine acidic FGF produced no neutralization of TGFPl activity.
On addition of antibody to TGFP to serum (Table 3) , the inhibitory effect of serum on the number and ploidy of megakaryocytes was fully neutralized. The Mean Ploidy,,, increased from 9.32 f. .33 to 11.98 f . .04 (plasma + antibody = 12.11 rf: .15) while the number of megakaryocytes increased from 77% ? 10% to 104% f 15% (plasma + antibody = 105% ? 9%). The addition of antibody to TGFP to plasma produced a small, reproducible but statistically insignificant increase in the number of megakaryocytes and no effect on the ploidy distribution. Addition of control rabbit antibodies to human PDGF and bovine acidic FGF did not neutralize the inhibitory effect of serum.
Treatment of serum with D I T also completely eliminated the inhibitory effect on megakaryocyte number and ploidy (data not shown).
TGFPI does not account for the differences found between thrombocytopenic and thrombocytotic rat plasma. Plasma prepared from thrombocytopenic (Table 4) or thrombocytotic (Table 5 ) rats produced the same total number of cells and megakaryocytes in culture (data not presented) but had opposing effects on the ploidy of megakaryocytes grown.
Plasma from thrombocytopenic rats ( Table 4) promoted an increase in megakaryocyte ploidy compared with that found with plasma from normal rats (P < .OS). Plasma from thrombocytotic rats (Table 5) failed to promote megakaryocyte ploidy growth equal to that seen with plasma from normal rats (P < .05). Addition of antibody to TGFP to plasma from normal, thrombocytopenic, or thrombocytotic rats had no effect on the ploidy distributions. Addition of equivalent amounts of control rabbit antibodies to human PDGF and bovine acidic FGF was also without effect. 
DISCUSSION
Although platelets contain by far the largest amount, TGFPl and its related compounds are produced in many
The synthesized, biologically inactive, latent form becomes biologically active on exposure to proteases. Once activated, TGFP displays an enormous range of biologic properties ranging from preventing the adipocyte differentiation of fibroblast^^^ to reversing ischemic injury to use only. Cultures were grown as described in Materials and Methods in the presence of erythropoietin (2 U/mL). Data are shown SD. n = The number of independent specimens analyzed for each condition in this experiment. The entire experiment has been performed over 10 times with the same results.
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Statistical significance: *P < ,001 compared with plasma (15%); tP < .05 compared with plasma (15%); SP < .05 compared with plasma (30%).
endothelial cells46 to mediating wound-related Rous sarcoma virus tum~rigenesis.~'
In the hematopoietic system, TGFPl has so far been shown to have primarily inhibitory activity on early, but not late, growth factor-mediated responses.a It inhibits the number of CFU-E:' BFU-E?l CFU-GEMM,3'34' and CFU~k.27.28.30~3 I The effect on CFU-GM has been reported to be stimulatory,28 inhibitory?@ or absent (but with a shift from macrophage to granulocyte differentiation3'). Ishibashi et alZ7 have shown that TGFPl decreased the amount of acetylcholinesterase (a marker of murine megakaryocytes) in a liquid culture assay and reduced the size of isolated single megakaryocytes. Mitjavila et a1*' also found that TGFPl reduced megakaryocyte cell size. However, Solberg et a13' did not find any suppression of megakaryocyte DNA synthesis with TGFP1. When administered to mice in v~vo,~' TGFpl produced a 95% decrease in the platelet count within 7 days as well as a 50% drop in hematocrit with a 100% increase in the white blood cell count over 14 days. We have recently developed a rat bone marrow culture system in which the number and ploidy of megakaryocytes that grow can be precisely quantitated using flow cytometry.5~'8~29 With this assay we have examined the effect of purified TGFPl on megakaryocyte growth. We found that purified TGFpl inhibited the number of megakaryocytes which grew at a half-maximal concentration of 0.66 ng/mL, a concentration at which others have observed inhibition of CFU-Mk.27,28,3' In addition, we have shown that at a halfmaximal concentration of 0.14 ng/mL TGFPl also inhibited megakaryocyte endomitosis. Because megakaryocyte endomitosis is not an early event in megakaryocyte differentiation, our results show that this effect is an exception to the observation4' that TGFPl affects only early events in hematopoiesis. Moreover, the sensitivity of endomitosis to TGFpl may provide an explanation for the rapid, early decrease in the platelet count after the administration of TGFpl in vivo. 49 The effects of TGFPl in our culture system are not lineage-specific. Erythropoietin-dependent erythropoiesis is inhibited half-maximally at a concentration (0.125 ng/ mL) virtually identical with that for the inhibition of megakaryocyte endomitosis. But, as also reported by othe r~, "~~' GM-CSF-dependent myeloid cell growth showed no inhibition by TGFP1. Furthermore, we have demonstrated that unlike some other effects of TGFp,36 the inhibition of megakaryocyte and erythroid growth is not potentiated by EGF.
Given this potent effect of TGFPl on megakaryocyte growth, we subsequently sought to determine whether the presence of TGFPl might account for the inability of megakaryocytes to grow in several different experimental conditions. In the first of these situations, we have sought to explain the failure of megakaryocytes to grow in the presence of serum. Serum and platelet lysates but not plasma have been shown to inhibit CFU-Mk acetylcholinesterase activity in liquid culture:7 CFU-E," and the number and ploidy of megakaryocytes."~2y Given the abundance of TGFpl and PF-4 in platelets, it has been s~g g e s t e d~'~~'~~~ that TGFpl and/or PF-4 account for this inhibitory activity. We have used a neutralizing antibody to use only. Cultures were grown as described in Materials and Methods in the presence of erythropoietin (2 U/mL). Data are shown c SD. n = The number of independent specimens analyzed for each condition in this experiment. The entire experiment has been performed 10 times with the same results.
For the relative number of megakaryocytes 100% = 6,184 f 291.
Statistical significance: *P < .01 compared with plasma; tP < .05 compared with plasma.
TGFP to show that TGFP1, not PF-4, accounts for all the inhibitory effect of rat serum on megakaryocyte number and ploidy. Presumably latent TGFPl is released from platelet (Y granules during clotting and is acted on by platelet or serum proteases to produce the biologically active molecule. We next examined the potential role of activated TGFPl as a circulating physiologic inhibitor of megakaryocyte growth." We have previouslg shown the existence of a humoral substance(s) in the circulation of the rat that increases the ploidy of megakaryocytes grown in thrombocytopenic plasma and decreases the ploidy of megakaryocytes grown in thrombocytotic plasma. We sought to determine whether the physiologic release from platelets into the circulation (or the nonphysiologic release during blood collections5) of TGFPl might account for these differences. Addition of antibody to TGFP to plasma from normal or thrombocytotic rats did not increase the ploidy of megakaryocytes grown in culture, as would have been expected had the differences between the plasmas been due to variations in the level of TGFP1.
Because megakaryocytes synthesize abundant amounts of TGFpl? the final situation we examined was whether autocrine release of activated TGFPl from megakaryocytes during culture might affect megakaryocytopoiesis in vitro. Under conditions of "GF-stimulated" or unstimulated megakaryocytopoiesis in our culture system, the addition of antibody to TGFP did not alter the number or ploidy of megakaryocytes that grew. In addition, the medium conditioned by these cultures did not contain detectible amounts of TGFPl even after acidification (D.J.K., unpublished observation, July 1989). Therefore, these results do not support an autocrine role of activated TGFPl in megakaryocyte growth and endomitosis in vitro.
The potent inhibitory effect of TGFPl poses a number of problems for those studying megakaryocytes and the regulation of their growth. At a practical level, effort must be made to use plasma (or plasma-derived serum) that is devoid of platelet products. If not possible, then treatment of samples with DTT or neutralizing antibody will eliminate activated TGFP. Furthermore, when attempting to demonstrate circulating humoral activities directed against megakaryocytes, great care must be exercised in collecting blood from animals to prevent platelet secretion and subsequent TGFPl activation.
Because the inhibitory effect of any molecule is defined in the context of known or unknown countervailing stimulatory molecules, the optimal inhibitory effect of any molecule is demonstrated in vitro by using culture systems that are maximally stimulated. To maximize megakaryocyte growth we have used erythropoietin while others have used IL-3 or medium conditioned by pokeweed mitogenstimulated spleen cellsz7 or by various cell lines.28 However, because the physiologic stimulator of megakaryocyte growth has not yet been identified, it is important to ask whether the described effects of TGFpl have physiologic relevance. 
